Close

pCDCAR1 PSCA h(ζ) (CAR-YF414)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-PSCA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human PSCA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PSCA antibody linked to and CD3ζ signaling domains. And the vector product was designed for the treatment of Prostate Cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • PSCA
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • Prostate Cancer
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-CD3ζ
  • Discription of Signaling Cassetes
  • CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD21-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • hu1G8
  • Host
  • Humanized
  • Target Species
  • Human
  • Gene Name
  • prostate stem cell antigen
  • Synonyms
  • PSCA;PSCA; prostate stem cell antigen; PRO232;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 After treatment with PBS or 1G8 (20 Ag/mL) for 24 hours, cells were stained with Annexin V and PI and analyzed by FACS.

CAR Construction : Latest CAR Construction

Fig.1 After treatment with PBS or 1G8 (20 Ag/mL) for 24 hours, cells were stained with Annexin V and PI and analyzed by FACS.

1G8 induces cell death.

Gu, Z., Yamashiro, J., Kono, E., & Reiter, R. E. (2005). Anti–prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer research, 65(20), 9495-9500.

Complete CAR data FCM

Fig.2 Generation of anti-prostate stem cell antigen (PSCA) CAR-T cells.

CAR Construction : 1G8 scFv-28ζ Latest CAR Construction

Fig.2 Generation of anti-prostate stem cell antigen (PSCA) CAR-T cells.

Representative flow cytometric analyses of transfected T cells detected by flow cytometry.

Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11.

Complete CAR data Cyt

Fig.3 Anti-PSCA CAR-T cells exhibited dramatic antitumor efficacy ex vivo.

CAR Construction : 1G8 scFv-28ζ Latest CAR Construction

Fig.3 Anti-PSCA CAR-T cells exhibited dramatic antitumor efficacy ex vivo.

The lytic capacity towards MKN-28 cells, was analyzed at the indicated effector-to-target ratios in a 24 h lysis assay.

Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11.

Complete CAR data FuncS

Fig.4 Anti-PSCA CAR-T cells efficiently reduced tumor progression in BGC-823 models.

CAR Construction : 1G8 scFv-28ζ Latest CAR Construction

Fig.4 Anti-PSCA CAR-T cells efficiently reduced tumor progression in BGC-823 models.

Percentage of T cells in the spleen of the BGC-823 models and representative FACS plots of the i.v group and the p.t group, respectively.

Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11.

Complete CAR data Inhibit

Fig.5 Anti-PSCA CAR-T cells suppressed tumor progression in MKN-28 model.

CAR Construction : 1G8 scFv-28ζ Latest CAR Construction

Fig.5 Anti-PSCA CAR-T cells suppressed tumor progression in MKN-28 model.

Schematic representation depicting the time course of the experiment.

Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-PSCA (hu1G8) h(-CD3ζ) CAR, pCDCAR1 (CAR-YF414). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.